Evidence map›Paper›PMID 41625493›Full record

ArticleBioactive materials2026

An AI-assisted designed supramolecularly engineered nanoplatform reverses pigmentation by triggering an ineffective compensatory melanin production program.

Tianqi Liu, Liang Chen, Xiaoyu Zhao, Min Xie, Ling Xie, Mi Wang, Zhenyuan Wang, Jiaheng Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianqi LiuSchool of Biomedical Engineering, Harbin Institute of Technology, Shenzhen, 518055, China.
Liang ChenScientific Research Laboratory, Shanghai Le-Surely Biotechnology Co., Ltd, Shanghai, China.
Xiaoyu ZhaoSchool of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Min XieScientific Research Laboratory, Shanghai Le-Surely Biotechnology Co., Ltd, Shanghai, China.
Ling XieScientific Research Laboratory, Shanghai Le-Surely Biotechnology Co., Ltd, Shanghai, China.
Mi WangSauvage Laboratory for Smart Materials, School of Materials Science and Engineering, Harbin Institute of Technology, Shenzhen, 518055, China.
Zhenyuan WangShenzhen Shinehigh Innovation Technology Co., Ltd., Shenzhen 518055, China.
Jiaheng ZhangSauvage Laboratory for Smart Materials, School of Materials Science and Engineering, Harbin Institute of Technology, Shenzhen, 518055, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical applications of natural compounds are limited by their inherent physicochemical properties. This study reports a hierarchical supramolecular engineering strategy for constructing a dual-assembly nanosystem for the treatment of skin hyperpigmentation. Using an AI-assisted computational screening model, tranexamic acid was identified as a suitable molecular partner of the hydrophobic and active, baicalin. Subsequent dual assembly processes yielded a stable hybrid nanoplatform (DHBTC) that enhanced the solubility and delivery efficiency of baicalin. Single-cell transcriptomics revealed an unexpected mechanism of "functional inhibition"; despite the depigmenting efficacy of DHBTC, the melanogenesis-related gene network in melanocytes was upregulated. This was identified as compensatory transcriptional feedback triggered by drug-induced autophagy. DHBTC functionally inhibits pigment accumulation by accelerating melanosome degradation, which elicits ineffective transcriptional activation as the cell attempts to restore homeostasis. Furthermore, the platform remodeled the cutaneous immune microenvironment toward an anti-inflammatory state. This study presents a strategy for designing drug delivery systems, from computational prediction to supramolecular assembly, and describes a therapeutic mechanism based on the modulation of post-translational and organellar homeostasis.

Indexed as

AI-Assisted designFunctional inhibitionHyperpigmentationSupramolecular assemblyTransdermal delivery

Identifiers

PMID41625493
PMCPMC12860373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.